{
  "id": 889934,
  "title": "Biogen's monoclonal antibody felzartamab wins first global approval in China",
  "url": "https://urgent.news/2026/08/14/biogens-monoclonal-antibody-felzartamab-wins-first-global-approval-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-14T17:11:14.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/biogens-monoclonal-antibody-felzartamab-wins-first-global-approval-in-china/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Biogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma. Felzartamab will be available in China for second-line multiple myeloma patients alongside lenalidomide and the corticosteroid dexamethasone. Yesterday's approval comes just ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}